{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-333912","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2026-08-05T12:05:10+00:00","discovered_at":"2026-08-05T12:10:00.335872+00:00","generated_at":"2026-08-05T12:10:10.702735+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ImageneBio Q2 2026 net loss $10.2M ($0.63/sh); cash $136.2M funds into Q1 2028","bullets":["Net loss of $10.2M ($0.63 loss per share) vs $10.7M ($4.46) in Q2 2025.","Cash, equivalents and marketable securities $136.2M as of June 30, 2026.","R&D expenses $6.7M (up from $5.7M); G&A expenses $5.1M (up from $1.7M) YoY.","Phase 2b ADAPTIVE trial for olevaprubart in atopic dermatitis on track; topline data expected Q4 2027.","Appointed Yanina Grant-Huerta as CFO and Matt Robbins as General Counsel in July 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-333912","json":"https://secwatch.observer/filing/0001193125-26-333912.json","markdown":"https://secwatch.observer/filing/0001193125-26-333912.md","text":"https://secwatch.observer/filing/0001193125-26-333912.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312526333912/0001193125-26-333912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312526333912/d166048d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T12:10:10.702735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}